Susquehanna Fundamental Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Susquehanna Fundamental Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-83,183	Closed	-$10.3M	–	872
2025 Q1	$10.3M	Sell	83,183 -10	-0%	-$1.3K	0.14%	180
2024 Q4	$10.2M	Buy	+83,193	New	+$9.81M	0.15%	186
2024 Q2	$11.4M	Buy	+106,750	New	+$11.7M	0.26%	112
2021 Q3	–	Sell	-13,925	Closed	-$2.47M	–	1790
2021 Q2	$2.47M	Buy	13,925 +22	+0.2%	+$3.81K	0.05%	528
2021 Q1	$2.29M	Sell	13,903 -8,649	-38%	-$1.42M	0.04%	593
2020 Q4	$3.72M	Sell	22,552 -5,439	-19%	-$810K	0.07%	420
2020 Q3	$3.99M	Buy	+27,991	New	+$3.47M	0.12%	237

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Susquehanna Fundamental Investments's JAZZ Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 83,183 shares — an estimated $10.3M sold.

Susquehanna Fundamental Investments first reported a position in JAZZ in Q3 2020 and held it in 7 quarters. The position peaked at $11.4M in Q2 2024. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 83,183 Jazz Pharmaceuticals shares in Q2 2025, an estimated $10.3M.
Susquehanna Fundamental Investments first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 7 quarters.
Susquehanna Fundamental Investments's Jazz Pharmaceuticals position peaked at $11.4M in Q2 2024.
501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.